HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill

 
• By Cathy Kelly

Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.

Resurrected Drug Pricing Bill May Have Path To Passage • Source: Shutterstock

More from Pricing Debate

More from Market Access